|
GlaxoSmithKline (GSK), Theravance (THRX) Announces US FDA Approval of …
StreetInsider.com GlaxoSmithKline (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) announced that the US Food and Drug Administration (FDA) has approved BREO ELLIPTA (fluticasone furoate/vilanterol [FF/VI]) for the once-daily treatment of asthma in patients aged 18 … Glaxo Wins U.S. Approval to Sell Breo Only to Adults With Asthma FDA approves Glaxo's inhaler drug Breo Ellipta for new use in treating adults … |
View full post on asthma – Google News